The precise identification of actual PD-L1-positive cases is crucial, as PD-L1 inhibitors are used as first-line monotherapy in non-small cell lung cancer (NSCLC) for patients with at least 50% PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.